![](https://hbhi.jhu.edu/sites/default/files/styles/highlights/public/2022-12/Publications_2.png?h=a31ffb6c)
Publication
The Price Paradox of Biosimilar-Like Long-Acting Insulin
Findings suggest that Basaglar was not less expensive for patients than Lantus. Empirical evaluation of biosimilar costs prior to automatic substitution is necessary.